case 3:03-cv-03709-si document 414 filed 09/05/2006 page 1...
TRANSCRIPT
![Page 1: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/1.jpg)
ATTORNEYS AT LAW
SILI CON VALLEY
CASE NO. C-03-3709-SI(EMC) DECLARATION OF LUI-KWAN ISO OPPOSITION TO REQUEST TO ALTER PROTECTIVE ORDER
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
LATHAM & WATKINS LLP Paul H. Dawes (Bar No. 55191) John C. Tang (Bar No. 212371) Michele D. Johnson (Bar No. 198298) Kalama M. Lui-Kwan (Bar No. 242121) Peter T. Snow (Bar No. 222117) 140 Scott Drive Menlo Park, California 94025 Telephone: (650) 328-4600 Facsimile: (650) 463-2600 Counsel for CV Therapeutics, Inc. and the Individual Defendants
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION
IN RE CV THERAPEUTICS, INC. SECURITIES LITIGATION This Document Relates To: All Actions
Master File No. C-03-3709-SI(EMC) CLASS ACTION DECLARATION OF KALAMA M. LUI-KWAN IN SUPPORT OF DEFENDANTS’ OPPOSITION TO PLAINTIFF’S FIFTH REQUEST TO ALTER PROTECTIVE ORDER
Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 of 4
![Page 2: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/2.jpg)
ATTORNEYS AT LAW
SILI CON VALLEY
CASE NO. C-03-3709-SI(EMC) DECLARATION OF LUI-KWAN ISO OPPOSITION TO REQUEST TO ALTER PROTECTIVE ORDER
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
I, Kalama M. Lui-Kwan, declare as follows:
1. I am an attorney with Latham & Watkins LLP (“Latham”), counsel for defendants
CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel K. Spiegelman (“Defendants”). I
make this declaration in support of Defendants’ Opposition to Plaintiff’s Fifth Request to Alter
Protective Order. The facts set forth herein are within my personal knowledge.
Correspondence Regarding Plaintiff’s First Request
2. On August 16, 2006, Plaintiff sent Defendants a letter requesting approval to
disclose certain documents to two experts, Shalini Gera and Zoë Beh (“August 16, 2006
Request”). Attached to the August 16, 2006 Request are a list of documents Plaintiff requested
approval to disclose to his experts, and two biographies of Mss. Gera and Beh. Attached as
Exhibit 1 is a true and correct copy of Plaintiff’s August 16, 2006 Request.
3. On August 17, 2006, Defendants sent a letter to Plaintiff requesting information
required by ¶¶ 7.4(a)(2)-(5) of the February 7, 2005 Protective Order (“August 17, 2006 Letter”).
Attached as Exhibit 2 is a true and correct copy of Defendants’ August 17, 2006 Letter.
4. On August 18, 2006, Plaintiff sent Defendants a letter responding to the August
17, 2006 Letter (“August 18, 2006 Letter”). Attached as Exhibit 3 is a true and correct copy of
Plaintiff’s August 18, 2006 Letter.
5. On August 21, 2006, Defendants sent Plaintiff a letter responding to the August
18, 2006 Letter (“August 21, 2006 Letter”). Attached as Exhibit 4 is a true and correct copy of
Defendants’ August 21, 2006 Letter.
6. On August 25, 2006, Defendants sent Plaintiff a letter objecting to the August 16,
2006 Request (“August 25, 2006 Objections”). Attached as Exhibit 5 is a true and correct copy
of Defendants’ August 25, 2006 Objections.
7. On August 28, 2006, Plaintiff sent Defendants a letter responding to the August
25, 2006 Objections (“Plaintiff’s August 28, 2006 Letter”). Attached as Exhibit 6 is a true and
correct copy of Plaintiff’s August 28, 2006 Letter.
8. On August 28, 2006, Defendants sent Plaintiff a letter responding to the August
Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 2 of 4
![Page 3: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/3.jpg)
ATTORNEYS AT LAW
SILI CON VALLEY
CASE NO. C-03-3709-SI(EMC) DECLARATION OF LUI-KWAN ISO OPPOSITION TO REQUEST TO ALTER PROTECTIVE ORDER
2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
28, 2006 Letter (“Defendants’ August 28, 2006 Letter”). Attached as Exhibit 7 is a true and
correct copy of Defendants’ August 28, 2006 Letter.
Plaintiff’s Second and Third Requests
9. On August 25, 2006, Plaintiff sent Defendants a letter requesting approval to
disclose certain documents to one expert, James Cunha (“August 25, 2006 Request”). Attached
to the August 25, 2006 Request are a list of documents Plaintiff requested approval to disclose to
his expert, and Mr. Cunha’s resumé. Attached as Exhibit 8 is a true and correct copy of
Plaintiff’s August 25, 2006 Request.
10. On August 28, 2006, Plaintiff sent Defendants a letter requesting approval to
disclose certain documents to one expert, Bjorn Steinholt (“August 28, 2006 Request”).
Attached to the August 28, 2006 Request are a list of documents Plaintiff requested approval to
disclose to his expert, Mr. Steinholt’s resumé, and a Declaration of Bjorn I. Steinholt. Attached
as Exhibit 9 is a true and correct copy of Plaintiff’s August 28, 2006 Request.
Defendants’ Document Productions
11. Defendants have made six significant document productions in this litigation and
delivered most of the documents at issue in productions more than a year ago. I prepared the
table below, which identifies the (1) date of each production, (2) ending bates number of each
production, and (3) number of documents in each production that Plaintiff now seeks approval to
disclose.
Production Date Ending Bates Number Number of Documents Plaintiff Seeks to Disclose
February 7, 2005 CVT 00442896 5 March 1, 2005 CVT 00529301 23
August 25, 2005 CVT 00856395 2 March 1, 2006 CVT 01532749 0 April 25, 2006 CVT 01836258 4 June 29, 2006 CVT 02411627 1
CVT’s Press Release
12. Upon information and belief, on January 27, 2006, CVT issued a press release
entitled “FDA Approves Ranexa” (“January 27, 2006 Press Release”). Attached as Exhibit 10 is
a true and correct copy of CVT’s January 27, 2006 Press Release.
Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 3 of 4
![Page 4: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/4.jpg)
ATTORNEYS AT LAW
SILI CON VALLEY
CASE NO. C-03-3709-SI(EMC) DECLARATION OF LUI-KWAN ISO OPPOSITION TO REQUEST TO ALTER PROTECTIVE ORDER
3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
I declare under penalty of perjury under the laws of the State of California and the United
States of America that the foregoing is true and correct and that this declaration was executed on
September 5, 2006 at Menlo Park, California.
/S/ Kalama M. Lui-Kwan
SV\521804.1
Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 4 of 4
![Page 5: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/5.jpg)
![Page 6: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/6.jpg)
![Page 7: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/7.jpg)
![Page 8: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/8.jpg)
![Page 9: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/9.jpg)
![Page 10: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/10.jpg)
![Page 11: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/11.jpg)
![Page 12: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/12.jpg)
![Page 13: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/13.jpg)
![Page 14: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/14.jpg)
![Page 15: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/15.jpg)
![Page 16: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/16.jpg)
![Page 17: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/17.jpg)
![Page 18: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/18.jpg)
![Page 19: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/19.jpg)
![Page 20: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/20.jpg)
![Page 21: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/21.jpg)
![Page 22: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/22.jpg)
![Page 23: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/23.jpg)
![Page 24: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/24.jpg)
![Page 25: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/25.jpg)
![Page 26: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/26.jpg)
![Page 27: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/27.jpg)
![Page 28: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/28.jpg)
![Page 29: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/29.jpg)
![Page 30: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/30.jpg)
![Page 31: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/31.jpg)
![Page 32: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/32.jpg)
![Page 33: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/33.jpg)
![Page 34: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/34.jpg)
![Page 35: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/35.jpg)
![Page 36: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/36.jpg)
![Page 37: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/37.jpg)
![Page 38: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/38.jpg)
![Page 39: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/39.jpg)
![Page 40: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/40.jpg)
![Page 41: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/41.jpg)
![Page 42: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/42.jpg)
![Page 43: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/43.jpg)
![Page 44: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/44.jpg)
![Page 45: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/45.jpg)
![Page 46: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/46.jpg)
![Page 47: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/47.jpg)
![Page 48: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/48.jpg)
![Page 49: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/49.jpg)
![Page 50: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/50.jpg)
![Page 51: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/51.jpg)
![Page 52: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/52.jpg)
![Page 53: Case 3:03-cv-03709-SI Document 414 Filed 09/05/2006 Page 1 ...securities.stanford.edu/.../CVTX03-01/...033709.pdf · CV Therapeutics, Inc. (“CVT”), Louis G. Lange, and Daniel](https://reader034.vdocument.in/reader034/viewer/2022042223/5eca3165837f870960088acc/html5/thumbnails/53.jpg)